Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 4:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Norovirus Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers

NCT03125473
View directory record Official record
Conditions
Norovirus Gastroenteritis
Interventions
VXA-G1.1-NN Oral Vaccine
Biological
Lead sponsor
Vaxart
Industry
Eligibility
19 Years to 49 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Jun 25, 2026, 4:12 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis

NCT06592794
View directory record Official record
Conditions
Acute Gastroenteritis, Norovirus Acute Gastroenteritis
Interventions
mRNA-1403, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37,864 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
184
States / cities
Birmingham, Alabama • Cullman, Alabama • Daphne, Alabama + 136 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jun 25, 2026, 4:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Norwalk Vaccine Study

NCT00806962
View directory record Official record
Conditions
Norovirus
Interventions
Adjuvant/Excipients, placebo, Norwalk VLP Vaccine
Drug · Device · Biological
Lead sponsor
LigoCyte Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Baltimore, Maryland • St Louis, Missouri • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Jun 25, 2026, 4:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

New Challenge Pool of Norwalk Virus Inoculum

NCT00138476
View directory record Official record
Conditions
Gastroenteritis Norovirus
Interventions
Placebo, Norwalk Virus
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Jun 25, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine

NCT02475278
View directory record Official record
Conditions
Norovirus, Healthy Participants
Interventions
NoV GI.1/GII.4 Bivalent VLP Vaccine
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2018 · Synced Jun 25, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Results available

NNITS-Nitazoxanide for Norovirus in Transplant Patients Study

NCT03395405
View directory record Official record
Conditions
Gastroenteritis Norovirus
Interventions
Nitazoxanide, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
12
States / cities
Chicago, Illinois • Kansas City, Kansas • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Jun 25, 2026, 4:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Infectivity of Norovirus in Shellfish Treated With High Hydrostatic Pressure Processing-Human Challenge Study

NCT00674336
View directory record Official record
Conditions
Healthy
Interventions
High Hydrostatic Pressure Processing
Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Jun 25, 2026, 4:12 PM EDT
Recruiting Phase 1 Interventional

Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts

NCT04691622
View directory record Official record
Conditions
Viral Infection, Hematopoietic Stem Cell Transplantation (HSCT), Primary Immunodeficiency Disorders (PID)
Interventions
Norovirus -specific T-cell (NST) therapy
Biological
Lead sponsor
Children's National Research Institute
Other
Eligibility
3 Months to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Jun 25, 2026, 4:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine

NCT04854746
View directory record Official record
Conditions
Norovirus Infections
Interventions
VXA-GI.1.NN, Placebo Tablet
Biological
Lead sponsor
Vaxart
Industry
Eligibility
55 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Cypress, California • New Orleans, Louisiana • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Jun 25, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population

NCT02661490
View directory record Official record
Conditions
Norovirus
Interventions
Norovirus GI.1/GII.4 Bivalent VLP Vaccine, 0.9% sodium chloride (saline)
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Littleton, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated May 17, 2020 · Synced Jun 25, 2026, 4:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose Range Evaluation of Norovirus Challenge Pool (GII.4, CIN-1)

NCT01435811
View directory record Official record
Conditions
Norovirus Infections
Interventions
Norovirus challenge pool (GII.4, CIN-1)
Biological
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Jun 25, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers

NCT05626803
View directory record Official record
Conditions
Norovirus Infections
Interventions
Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose, Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose, Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose, Placebo
Drug
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 80 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
3
States / cities
Long Beach, California • Lenexa, Kansas • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 14, 2025 · Synced Jun 25, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults

NCT02669121
View directory record Official record
Conditions
Healthy Volunteers
Interventions
NoV Placebo-matching Saline, NoV GI.1/GII.4 Bivalent VLP Vaccine
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 49 Years
Enrollment
4,748 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Great Lakes, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Jun 25, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults

NCT02142504
View directory record Official record
Conditions
Norovirus Prevention
Interventions
Norovirus Bivalent VLP Vaccine, Placebo (Saline)
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 49 Years
Enrollment
454 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Coral Gables, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2017 · Synced Jun 25, 2026, 4:12 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Two Doses of HIL-214 in Children

NCT05281094
View directory record Official record
Conditions
Gastroenteritis
Interventions
HIL-214, Placebo
Biological
Lead sponsor
HilleVax
Industry
Eligibility
5 Months to 5 Months
Enrollment
3,084 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Jun 25, 2026, 4:12 PM EDT
Terminated Not applicable Interventional

Human Breastmilk in Young Children With Norovirus Infection of the Gut

NCT02371538
View directory record Official record
Conditions
Norovirus Infections
Interventions
Donor Breastmilk
Dietary Supplement
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Jun 25, 2026, 4:12 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Phase I Study to Determine the Optimal Human Challenge Dose for a Norovirus GII.4 Challenge Stock (CIN-1)

NCT02337842
View directory record Official record
Conditions
Gastroenteritis Norovirus
Interventions
Norovirus GII.4 Challenge Pool CIN-1, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Jun 25, 2026, 4:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers

NCT05213728
View directory record Official record
Conditions
Norovirus Infections
Interventions
VXA-G1.1-NN
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Jun 25, 2026, 4:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Infectivity of Norovirus in Groundwater-Human Challenge Study

NCT00313404
View directory record Official record
Conditions
Healthy
Interventions
Safety tested norovirus inoculum
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Jun 25, 2026, 4:12 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Norovirus Challenge Study

NCT05212168
View directory record Official record
Conditions
Norovirus Infections
Interventions
VXA-G1.1-NN, Placebo Tablets, Norovirus GI.1 Norwalk Virus Inoculum
Biological · Other
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Jun 25, 2026, 4:12 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old

NCT06944717
View directory record Official record
Conditions
Norovirus Infections
Interventions
VXA-G1.1-NN, VXA-G2.4-NS, VXA G1.1 NN-T, VXA G2.4 NS-T
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jun 25, 2026, 4:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Infectivity and Illness of Norwalk GI.1 Virus Lot 001-09NV in the Human Challenge Model

NCT03721549
View directory record Official record
Conditions
Norovirus Infection
Interventions
Norwalk GI.1 Virus
Biological
Lead sponsor
WCCT Global
Industry
Eligibility
18 Years to 49 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Costa Mesa, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Jun 25, 2026, 4:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine

NCT02868073
View directory record Official record
Conditions
Norovirus Gastroenteritis
Interventions
VXA-G1.1-NN (high dose) Oral Vaccine Tablet, VXA Placebo Tablets, VXA-G1.1-NN (low dose) Oral Vaccine Tablet
Biological · Other
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Jun 25, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults

NCT03039790
View directory record Official record
Conditions
Healthy Volunteers, Norovirus
Interventions
NoV Vaccine
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
9
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Littleton, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Jun 25, 2026, 4:12 PM EDT